"uuid:ID","instanceType","rationale","versionIdentifier","id"
"9b4133ac-0704-4b3b-b872-749c94a48c5f","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","StudyVersion_1"
